Bilateral ovarian gonadoblastoma with coexisting dysgerminoma in a girl with 46, XX karyotype

Gonadoblastoma is a rare gonadal tumor with tumor cells arranged in nests surrounded by ovarian stroma containing Leydig or lutein‐type cells. In 50% of the cases, there is an overgrowth of germ cells with progression to dysgerminoma. A case of gonadoblastoma with coexisting dysgerminoma developing...

Full description

Saved in:
Bibliographic Details
Published in:The journal of obstetrics and gynaecology research 2010-06, Vol.36 (3), p.697-700
Main Authors: Yilmaz, Bulent, Gungor, Tayfun, Bayramoglu, Hatice, Soysal, Sunullah, Mollamahmutoglu, Leyla
Format: Article
Language:English
Subjects:
adolescent
coexisting
dysgerminoma
Dysgerminoma - genetics
Dysgerminoma - pathology
Dysgerminoma - surgery
Female
gonadoblastoma
Gonadoblastoma - genetics
Gonadoblastoma - pathology
Gonadoblastoma - surgery
Humans
Karyotyping
Neoplasms, Multiple Primary - genetics
Neoplasms, Multiple Primary - pathology
Neoplasms, Multiple Primary - surgery
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Ovarian Neoplasms - surgery
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gonadoblastoma is a rare gonadal tumor with tumor cells arranged in nests surrounded by ovarian stroma containing Leydig or lutein‐type cells. In 50% of the cases, there is an overgrowth of germ cells with progression to dysgerminoma. A case of gonadoblastoma with coexisting dysgerminoma developing in both ovaries of a 20‐year‐old girl who had increased abdominal girth is presented here. A pelvic mass measuring 20 × 14 cm was detected by pelvic ultrasonography. Bilateral salphingo‐oophorectomy was performed. The histopathological report revealed bilateral gonadoblastoma with coexisting dysgerminoma. After surgery the patient received radiation and chemotherapy (BEP: bleomycin, etoposide, cisplatin) and was started on hormone replacement therapy. Five years and eight months after treatment, the patient is well and free of recurrence.
ISSN:1341-8076
1447-0756
DOI:10.1111/j.1447-0756.2010.01225.x